Audit: QRS - Eggshell Membrane for Health & Longevity
Audit conducted on 20/09/2026 20:06 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 82 |
| Failed | 0 |
| N/A | 11 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Every cell traces to ER text: protocol cells to ER Therapeutic Protocol, time cells to ER Practical Considerations and Expected Benefits, benefit/risk items to ER tier headings, gates to ER Key Interactions & Contraindications, markers and cadence to ER Monitoring Protocol & Defining Success. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | “No chronobiology data exist” and “split dosing is unstudied” mirror ER lines 340 and 344. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Contraindications retain absolute framing; interaction verdicts (“Caution”, “Monitor”) are carried over unchanged. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | No content from ER Benefit-Modifying Factors or Risk-Modifying Factors appears in the gates; gates draw solely on ER Key Interactions & Contraindications. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, NCT identifiers or brand names appear. “Sampson” and “Kellgren–Lawrence” appear in the ER contraindication bullets (ER lines 309, 312). |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions beyond those in the ER. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Sober, evidence-weighted register matching the ER Conclusion. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Presents the tolerability finding and the funding caveat side by side without hedging or exhortation. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Cells state what was studied, not what to do. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No imperative or prescriptive constructions outside the fixed template disclaimer. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | All entries are declarative statements of evidence. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns anywhere in the file. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms appear only where the ER itself requires them (marker names, drug classes). |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Benefit and risk items are reduced to ER tier headings; interaction items to label plus verdict. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed by scan for “you/your/we/our/us” — no matches. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Monitoring table, cadence and qualitative tracking list assume a self-directed, protocol-following reader. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Six-marker laboratory panel and repeat testing schedule are presented without simplification. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | No consumer-grade simplification or motivational framing. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | At-a-glance foregrounds the modest effect size and the sponsor-funding caveat, the decision-relevant facts for this audience. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | “Longevity” in title and header; “anti-aging” does not occur. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. | 🟢 | No lay route-of-administration or adverse-event phrasing; units and marker names use formal notation (kU/L, mg/L, mL/min/1.73 m²). |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All headings byte-identical to [qrs_template]; skeleton diff against the template shows no heading changes. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | Diff of span names shows full coverage; marker_#_* expanded to 1–6 and qualitative_item_# to 1–6 as intended. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | <span website="evidence_review">, <span website="audit"> and <span website="full_review"> are unchanged; CSS and head are byte-identical to the template. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No ER section drawn on by the QRS is empty. The only tier without items (ER Medium risks) is governed by item 13.5, which mandates display:none rather than empty-state phrasing. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol labels “Standard dose”, “Best time of day”, “Single versus split dosing” and all six interaction labels match the ER bold labels verbatim. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Time-to-effect labels are drawn from the ER’s own outcome wording; no label is abbreviated. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | Scan for emoji code points returns no matches. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section is compressed to its floor: benefits and risks to bare tier headings, interactions to label plus verdict, contraindications to the key fact plus mandated parenthetical. Remaining volume is content that items 4.2, 8.5, 9.5, 14.2 and 15.2 require to be retained. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–14, immediately after <!doctype html> on line 1. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- at line 3, closing --- at line 13. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; no metadata value is repeated in the header or footer. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:02" is quoted, correctly so because it contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: eggshell_membrane_2026-0920-1621_Opus_ER.md. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.9.11, matching the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0920-1952. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” — single word, no version. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” — nickname plus version, no qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9 matches the file’s actual name on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Confirmed across all nine keys. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: “Eggshell Membrane for Health & Longevity - Quick Reference Sheet”. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: “Eggshell Membrane for Health & Longevity”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: “09/20/2026”, matching qrs_creation_date: 2026-0920-1952. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: “Opus 5”. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header block matches the template exactly apart from the three substituted variables. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Compresses ER lines 453–457: composition, strongest claim, dosing shape, tolerability, allergy hazard, funding bias. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 56 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each clause maps to a distinct sentence in ER Conclusion (lines 453, 455, 457). |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; “cartilage”, “skin”, “stiffness”, “egg allergy” are everyday terms. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial named or dated. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | “modest relief” and “unusually fast” carry no numeric effect estimate. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All five items come from “Populations who should avoid Eggshell Membrane” (ER lines 308–312). |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All five ER avoid-populations are present, in ER order. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Lines 564–574: five <li> elements inside the span. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | ER trailing clauses (“where no trial has enrolled participants”, “which was excluded from every trial…”) are stripped; no dash-trailing clauses remain. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | The 2 kU/L ovomucoid threshold, Sampson grade 3–5 severity class and Kellgren–Lawrence grade 4 staging are all retained. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s contraindication bullets use no ranking notation inside parentheses. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
N/A | The section is populated; the ER names five avoid-populations. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All six items come from ER lines 294–304. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All six ER interaction bullets present; none overlaps the contraindication list. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Lines 582–606: six <li> elements inside the span. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Each item reduces to the ER bold label plus its verdict word (“Caution”, “Monitor”, “Caution against redundancy”); all mechanistic sentences are stripped. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | All five ER example-drug and example-supplement lists are retained in full, including the Boswellia serrata italicisation. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s interaction parentheticals are plain comma-separated lists with no ranking notation. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
N/A | The section is populated; the ER names six interactions. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells trace to ER Therapeutic Protocol (lines 332, 340, 344). |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Standard dose, best time of day and single-versus-split dosing are the three bullets that determine how the regimen is actually executed. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER Therapeutic Protocol section contains twelve bullets; all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine fields populated; each sub adds the ER’s own qualifier rather than filler. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Knee pain and stiffness, exercise-recovery discomfort and skin/hair measures are exactly the three onsets in the ER “Time to effect” bullet (line 387). |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Knee osteoarthritis relief is the ER’s sole High benefit and is first; the two Medium benefits follow in ER order. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct time-to-effect aspects exist; all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | “10 days”, “Day 4–8” and “4–12 weeks” with subs drawn from ER lines 160 and 387. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER does provide time-to-effect information, so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All fifteen items are ER benefit headings from lines 150–228. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present and populated (lines 534–554). |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each item is the bare ER heading; no SMD, confidence interval, p-value or sponsor note carried over. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear anywhere in the benefits card. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four ER benefit tiers contain items (1 High, 4 Medium, 2 Low, 8 Speculative). |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All four items are ER risk headings from lines 250–276. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present (lines 618–630). |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each item is the bare ER heading; toxicology and case-report detail is omitted. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear anywhere in the risks card. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | ER states “No risk reaches Medium” (line 258); line 621 correctly sets risks_medium to style="display: none" with no empty-state text. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Table and cadence both drawn from ER Monitoring Protocol & Defining Success (lines 413–422). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All six ER biomarker rows present, in ER order, with targets and rationales verbatim. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Lines 728–731 reproduce the ER cadence from line 413. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Drawn from the ER’s “Qualitative markers to track alongside the laboratory values” list (lines 426–431). |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All six ER qualitative markers present, in ER order, verbatim. |
Issues 20/09/2026 20:06
Pass rate 100.00%. No issues found.
Issues 20/09/2026 20:00
- 4.2 — NSAID label not verbatim: The Key Interactions label at QRS lines 592–593 reads “(NSAIDs: ibuprofen, naproxen, aspirin)” while the ER bold label at line 298 reads “(NSAIDs — ibuprofen, naproxen, aspirin)”; the em-dash was replaced with a colon, so the label is not carried over verbatim.
Fixes 20/09/2026 20:00
- 4.2 — NSAID label not verbatim: Restored the ER’s bold label verbatim in the Key Interactions gate, changing “(NSAIDs: ibuprofen, naproxen, aspirin)” back to “(NSAIDs — ibuprofen, naproxen, aspirin)”.
Issues 20/09/2026 19:58
- 4.3 — Time-to-effect label paraphrased:
time_2_label(line 505) reads “Exercise-related joint discomfort”, but the ER’s term is “Exercise-Induced Joint Discomfort” (ER line 158) and the QRS itself uses “exercise-induced” inbenefits_medium(line 539).
Fixes 20/09/2026 19:58
- 4.3 — Time-to-effect label paraphrased: Changed
time_2_labelfrom “Exercise-related joint discomfort” to “Exercise-induced joint discomfort”, matching the ER term and the QRS’s ownbenefits_mediumwording.